Clover Health Investments Corp Dossier - Source-backed chat

Clover Health Investments Corp

CLOVNASDAQ

SectorHealth Care

IndustryHealthcare Plans

Beta (adjusted)1.97

Intrinsic Value $4.28median of 3 methodsbased on filings through 30 Jun 2026

Market Price $4.23Price as of 1 Oct 2026

Near fair valueIntrinsic value is 1% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.2B

Enterprise Value $2.2B

Shares Outstanding 543.3M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Clover Health has successfully transitioned from a speculative, high-burn insurtech SPAC to a fundamentally sound, technology-driven Medicare Advantage operator on the cusp of full-year GAAP profitability. The core investment thesis centers on highly predictable cohort economics: while new members generate initial losses, returning cohorts achieve substantial profitability as the Clover Assistant AI platform drives early clinical diagnoses and reduces hospitalizations. This operational leverage is further amplified by the commercialization of its technology via Counterpart Health, offering a high-margin SaaS call option that is currently undervalued by the market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$5.00

Mean target$5.17

High · most bullish analyst$5.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The CMS Star Ratings downgrade to 3.5 Stars is upheld, creating a severe revenue headwind for 2027. Additionally, a spike in outpatient utilization or higher-than-expected medical costs among newly acquired cohorts dilutes margins, delaying the path to sustained GAAP profitability and forcing the company to consume its cash reserves.

Base CaseCentral scenario

The company successfully delivers on its full-year 2026 guidance, achieving its first full year of GAAP Net Income profitability ($0M - $20M) and sustaining robust Medicare Advantage membership growth. The Clover Assistant continues to improve returning member cohort economics, keeping the full-year Insurance Benefits Expense Ratio (BER) stable. The market begins to re-rate the stock as a viable, self-sustaining business rather than a speculative cash-burner.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proven Cohort Economics: Improving new member cohort economics and strong returning cohort performance, driven by Clover Assistant coverage and high member retention, position the company for compounding earnings.
Inflection to GAAP Profitability: Q1 2026 marked a significant milestone with $27 million in GAAP Net Income, validating the company's path to full-year profitability.
SaaS Optionality: The launch and commercialization of Counterpart Health provides a massive, high-margin software revenue stream that is largely unpriced.
Strong Balance Sheet: Clover maintains a solid financial position, achieving positive GAAP Net Income and Adjusted EBITDA profitability in Q1 2026, which supports its path to full-year profitability.

Key Investment Risks

Regulatory and CMS Star Ratings Risk: The downgrade of PPO plans to 3.5 Stars poses a significant headwind to 2027 bonus payments if not successfully appealed.
New Member Dilution: Rapid membership growth (up 51% YoY in Q1 2026) introduces short-term margin pressure due to first-year care engagement costs.
Concentration Risk: Clover's operations are highly concentrated in its core New Jersey market, leaving it vulnerable to regional competitive dynamics.

Thesis Invalidation Triggers

Failure to achieve positive GAAP Net Income for the full year 2026.
Complete stagnation in external customer acquisition for Counterpart Health over the next 12 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.